May 22, 2012

2012 Preview: Cancer Immunotherapy Catalysts

MD Becker Partners' Life Science Digest: 2012 graphic

2012 represents a period with robust news flow for emerging immuno-oncology companies

Baker’s Dozen Trying to Beat the Odds in Pancreatic Cancer

Pancreatic Cancer Image

November marks Pancreatic Cancer Awareness Month – a baker’s dozen are trying to beat the odds in treating the disease.

Three Late-Stage Leukemia Company Previews for ASCO

blood_slide

Three companies with late-stage development programs for the treatment of AML are expected to provide updates at the 2011 ASCO annual meeting.

To Partner, or Not to Partner: That is the Question

MD Becker Partners' Life Science Digest: To Partner, or Not to Partner - That is the Question

Traditional wisdom holds that biotechnology companies benefit from collaborations with their larger pharmaceutical peers, which can help validate a company’s technology, provide capital to help fund clinical development, and enable access to experienced clinical, regulatory and commercial infrastructure.  While this was certainly true in the early days of biotechnology, the industry has now matured – [...]

Merger Means Billions for Biotechnology?

MD Becker Partners' Life Science Digest: Merger Means Billions for Biotechnology?

In March 2009, we asked the question “Where Might Genentech Investors Redeploy $47 Billion?” in response to the news that Roche Holding AG (RHHBY.PK) would acquire the outstanding publicly held interest in Genentech for a total payment of approximately $47 billion in cash.   We hypothesized that investors seeking biotechnology companies of comparable size and liquidity [...]